Last Updated : May 13, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued Sort descending |
|---|---|---|---|---|---|---|
| Revolade | eltrombopag | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | |||
| Symdeko | tezacaftor/ivacaftor | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | |||
| TBC | etonogestrel | Prevention of pregnancy | Withdrawn | |||
| Tecentriq | Atezolizumab | Withdrawn | ||||
| Inlyta (RFA) | Axitinib | Metastatic Renal Cell Carcinoma | N/A | Complete | ||
| TBC | rozanolixizumab | Generalized myasthenia gravis (gMG). | Pending | |||
| Vanflyta | quizartinib | acute myeloid leukemia (AML) | Pending | |||
| Spevigo | spesolimab | generalized pustular psoriasis (GPP) | Pending | |||
| Alsitek | masitinib mesylate | Amyotrophic lateral sclerosis (ALS) | Suspended | |||
| Myalepta | metreleptin | Leptin deficiency in lipodystrophy | Active |
Last Updated : May 13, 2024